Browse studies

Find your next paid study

6 recruiting studies matching your filters

Phase II Study of Second-line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

The purpose of this study is to test any good and bad effects of the study drug, pembrolizumab, in combination with GVD in the treatment of Hodgkin lymphoma.

Hodgkin LymphomaRelapsed or Refractory Hodgkin Lymphoma

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT03618550

Phase 1

A Phase 1 Study of Nivolumab in Combination With ASTX727 in B-cell Lymphoma (NHL or HL) With an Expansion Cohort in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Hodgkin Lymphoma (HL)

This phase I trial tests the safety, side effects, and best dose of nivolumab in combination with ASTX727 in treating B-cell lymphoma that has come back (relap…

Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Hodgkin Lymphoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05272384

Phase 2

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

This is a single arm, open-label, multicenter, phase II study of pembrolizumab (pembro), gemcitabine, vinorelbine, and liposomal doxorubicin (GVD) in patients …

Hodgkin Lymphoma, AdultRefractory Hodgkin LymphomaClassic Hodgkin Lymphoma

Estimated

~$10 – $7,500

Michael Spinner, MDNCT07021989

Phase 1

A Phase 1, Open-label, Multicenter, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HCB301 in Subjects With Advanced Solid Tumors or Relapsed and Refractory cHL

The purpose of this study is to find out whether IV injection of HCB301 is an effective treatment for different types of advanced solid tumors and relapsed and…

Advanced Solid TumorRefractory Hodgkin Lymphoma

Estimated

~$10 – $8,750

FBD Biologics LimitedNCT06487624

Phase 2

A Phase II Study of the Combination of Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Relapsed Hodgkin Lymphoma (HL) and B-Non-Hodgkin- Lymphoma (B-NHL)

This is a Phase II single-center open label trial of the combination of ATRA and pembrolizumab treatment in patients with histologically proven, relapsed or re…

Relapsed Hodgkin LymphomaRefractory Hodgkin LymphomaRelapsed Non-Hodgkin Lymphoma+2 more

A Phase 2 Trial of Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy (aTac-BEAM) Conditioning for Autologous Hematopoietic Cell Transplantation (AHCT) in Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

This phase II trials studies the effects of yttrium-90 labeled anti-CD25 monoclonal antibody combined with BEAM chemotherapy conditioning in treating patients …

Recurrent Hodgkin LymphomaRefractory Hodgkin Lymphoma

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT04871607